Floatz logo

Omacetaxine

FLT3-ITD Mutation

The University of Hong KongPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the FLT3-ITD Mutation cohort.

Asset / SponsorPhaseRating
Gilteritinib
The First Affiliated Hospital of Soochow University
Phase 3BB
Cytosin-Arabinosid
First Affiliated Hospital of Zhejiang University
Phase 3BB
Azacitidine
French Innovative Leukemia Organisation
Phase 2BB
Sorafenib
The First Affiliated Hospital of Soochow University
Phase 3BB
Daunorubicin
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3BB

View all 23 →

Same molecule, other indications

Omacetaxine is also rated in:

Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic LeukemiaDormant
BB
Indicative ·
65 / 100
View asset →
Elderly Patients (60-75 Years)Dormant
B
Indicative ·
60 / 100
View asset →
Induction ChemotherapyDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →